UK price watchdog recommends against Amgen's Lumakras in lung cancer

RegulatorynegativeLumakrasNegative

AI Analysis

Summary

The UK's National Institute for Health and Care Excellence issued draft guidance recommending against reimbursement of Amgen's Lumakras for new lung cancer patients, representing a negative regulatory decision for the drug's market access.

Outcome Details

UK's National Institute for Health and Care Excellence recommended against government reimbursement of Lumakras for new patients

Importance:7/10

Sentiment:

-0.80

UK pricingreimbursementNICElung cancernegative recommendation

Related Companies

$AMGN $NHPAP

Read the original article

Published by Endpoints News on July 9, 2026 5:52 PM

Read Original